Compounds > gsk2485852
Page last updated: 2024-11-13

gsk2485852

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GSK2485852: inhibits hepatitis C virus polymerase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID53354790
CHEMBL ID3121193
SCHEMBL ID2294370
MeSH IDM0594163

Synonyms (19)

Synonym
CHEMBL3121193 ,
1pv ,
[4-({[5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-6-yl](methylsulfonyl)amino}methyl)-2-fluorophenyl]boronic acid
gsk5852
[4-[[[5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl]-methylsulfonyl-amino]methyl]-2-fluoro-phenyl]boronic acid
gsk2485852
SCHEMBL2294370
b-(4-(((5-cyclopropyl-2-(4-fluorophenyl)-3-((methylamino)carbonyl)-6-benzofuranyl)(methylsulfonyl)amino)methyl)-2-fluorophenyl)boronic acid
1331942-30-3
6G04C5ZNQJ ,
boronic acid, b-(4-(((5-cyclopropyl-2-(4-fluorophenyl)-3-((methylamino)carbonyl)-6-benzofuranyl)(methylsulfonyl)amino)methyl)-2-fluorophenyl)-
gsk-2485852
gsk-5852
unii-6g04c5znqj
boronic acid, b-[4-[[[5-cyclopropyl-2-(4-fluorophenyl)-3-[(methylamino)carbonyl]-6-benzofuranyl](methylsulfonyl)amino]methyl]-2-fluorophenyl]-
bdbm50495951
Q27452332
AKOS040748468
(4-((n-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-fluorophenyl)boronic acid

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Co-administration with food reduced the AUC and Cmax of GSK2485852 by 40% and 70%, respectively."( A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects.
Adkison, K; Baptiste-Brown, S; Gan, J; Kim, J; Lee, D; Lovern, M; Mathis, A; Moss, L; Shotwell, B; Spaltenstein, A; Voitenleitner, C; Walker, J; Wilfret, DA; Yu, L, 2014)		0.84
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RNA-directed RNA polymerase IC50 (µMol)0.13000.01902.52798.8000AID1070656
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID1070666Antiviral activity against wild type Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID1592190Half life in human hepatocytes at 0.5 uM by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1592187AUC in rat at 5 mg/kg, po by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1592213Half life in human assessed as 5-cyclopropyl-2-(4-fluorophenyl)-N-methyl-6-(methylsulfonamido)benzofuran-3-carboxamide level2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1592195Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1592188Oral bioavailability in rat at 5 mg/kg by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1592202Blood clearance in rat at 1 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1070667Antiviral activity against wild type Hepatitis C virus genotype 1a infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID1592193Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1070656Inhibition of Hepatitis C virus genotype 1b NS5B Cdelta21 RNA dependent RNA polymerase 316N mutant using biotinylated polyC:oligoG/[alpha-P33]-GTP as template/substrate preincubated for 15 mins followed by template/substrate addition by scintillation prox2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID1854470Antiviral activity against HCV GT1b C316Y assessed as reduction in viral replication2022European journal of medicinal chemistry, Oct-05, Volume: 240Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective.
AID1592203Blood clearance in Beagle dog at 1 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1592194Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1592208Blood clearance in rat at 1 mg/kg, iv by LC-MS/MS analysis relative to hepatic blood flow2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1592186Half life in rat at 1 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1070659Antiviral activity against wild type Hepatitis C virus genotype 1a harboring C316Y mutant infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID1070657Antiviral activity against wild type Hepatitis C virus genotype 1b harboring S365T mutant infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by Bright-glo luciferase reporter gene assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID1592192Inhibition of CYP2C19 in human liver microsomes using mephenytoin as substrate preincubated for 10 mins followed by NADPH addition and measured by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1592204Plasma clearance in cynomolgus monkey at 1 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1854466Antiviral activity against HCV GT1b assessed as reduction in viral replication2022European journal of medicinal chemistry, Oct-05, Volume: 240Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective.
AID1592185Volume of distribution at steady state in rat at 1 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1070665Antiviral activity against wild type Hepatitis C virus genotype 1b harboring C316N mutant infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID1592184Clearance in rat at 1 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1592206Plasma clearance in CD1 mouse at 1 mg/kg, iv by LC-MS/MS analysis relative to hepatic blood flow2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1592200Plasma clearance in CD1 mouse at 1 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1070653Inhibition of C-terminal 6xHis-tagged Hepatitis C virus genotype 1b BK NS5B Cdelta21 RNA dependent RNA polymerase L47Q/F101Y/K1148 mutant expressed in Escherichia coli BL21(DE3) using radiolabelled CTP/5'-A(8)CG-3' as substrate/template assessed as inhibi2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID1070654Binding affinity to Hepatitis C virus genotype 1b NS5B Cdelta21 RNA dependent RNA polymerase 316N mutant assessed as dissociation half life at 0.6 uM by LC-MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID1592210Plasma clearance in cynomolgus monkey at 1 mg/kg, iv by LC-MS/MS analysis relative to hepatic blood flow2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1592209Blood clearance in Beagle dog at 1 mg/kg, iv by LC-MS/MS analysis relative to hepatic blood flow2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1592212Antiviral activity against HCV genotype1 infected in human assessed as reduction in plasma viral RNA level at 420 mg, po administered as single dose2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1070664Inhibition of C-terminal 6xHis-tagged Hepatitis C virus genotype 1b BK NS5B Cdelta21 RNA dependent RNA polymerase L47Q/F101Y/K1148 mutant after 30 mins in presence of [alpha-33P]2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID1070658Antiviral activity against wild type Hepatitis C virus genotype 1b harboring C316F mutant infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by Bright-glo luciferase reporter gene assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
AID1592191Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 10 mins followed by NADPH addition and measured by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor.
AID1070660Antiviral activity against wild type Hepatitis C virus genotype 1b harboring C316Y mutant infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by Bright-glo luciferase reporter gene assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.64 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (20.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		2.0810
hcv 796
HCV 796: inhibits HCV RdRp; structure in first source		3.9330
gs-9669
[no description available]		3.5110
ConditionIndicatedRelationship StrengthStudiesTrials
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
[description not available]		03.3310
Hepatitis C
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.		03.3310
Chronic Hepatitis C
[description not available]		03.8821
Hepatitis C, Chronic
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.		03.8821